Iovance Biotherapeutics Inc
NASDAQ:IOVA
Iovance Biotherapeutics Inc
NASDAQ:IOVA
Price:
10.045 USD
-2.76%
Market Closed
Updated:
May 23, 2024
Iovance Biotherapeutics Inc
Net Income (Common)
|
Iovance Biotherapeutics Inc
Net Income (Common) Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Iovance Biotherapeutics Inc
NASDAQ:IOVA
|
Net Income (Common)
-$449.6m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-29%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$484m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-20%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$3.8B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$3.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
26%
|
See Also
What is Iovance Biotherapeutics Inc's Net Income (Common)?
Net Income (Common)
-449.6m
USD
-449.6m
USD
Based on the financial report for Mar 31, 2024, Iovance Biotherapeutics Inc's Net Income (Common) amounts to -449.6m USD.
What is Iovance Biotherapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-29%
-29%
Over the last year, the Net Income (Common) growth was -9%. The average annual Net Income (Common) growth rates for Iovance Biotherapeutics Inc have been -19% over the past three years , -27% over the past five years , and -29% over the past ten years .
You don't have any saved screeners yet
